Analyst sees bright future for Novaliq and Bausch and Lomb dry eye treatments

18 October 2022

A broad set of mechanisms of action (MOAs) are being explored by drug developers in dry eye syndrome (DES), analysis from GlobalData shows.

The data and analytics company has taken a look at late-stage pipeline therapies that are currently in development for treating DES, the market for which was worth $4 billion in 2018 across the seven major markets of the USA, Japan and Europe’s five leading economies.

This is expected to grow to $14.8 billion in 2028 at a compound annual growth rate of 13.8%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK